Loading stock…

EyePoint, Inc. (EYPT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

EyePoint, Inc.

EYPTMarket cap $0.29BPrice $3.3

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops sustained-release drug therapies for eye diseases, using its Durasert technology to deliver medication for months from a single injection. Its lead treatment targets wet AMD, tapping into a market where patients dread frequent eye injections.

In Bastion Portfolios?

52W Return-71%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-9%1

Revenue Forecast

Rev CAGR (1y)-95%1

Rev CAGR (3y)+34%10

Rev CAGR (5y)+66%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-11369%1

Net Income Margin-10999%1

Free Cash Flow Margin-9730%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-149%1

ROA-116%1

Earnings Stabilityna–

GEAR+VERY WEAK4

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV1.77

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-94.8%1

Dividend Yieldna–

Momentum

Short term

1 month return-27%1

3 month return-76%1

YTD return-82%1

Mid term

Price vs 52wHigh17%1

1 year return-76%1

Long term

3 year return-61%1

5 year return-68%1

Risk Shield

Price Risk

Beta2.31

Volatility133%1

Free Cash Flow

Free Cash Flow Margin-9730%1

Free Cash Flow Yield-94.8%1

Quality

ROCE-140%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

EYPTEyePoint

Revenue FY25$31M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-9%1

Revenue, next 1Y-95%1

Revenue, next 3Y, CAGR+34%10

Revenue, next 5Y, CAGR+66%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 34%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 34%/yr from here.

The runway holds up: revenue is set to grow 66%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

WEAKNESSES

Revenue fell 9%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-27%1

3-month return-76%1

YTD return-82%1

MID & LONG-TERM▾SCORE

% of 52-week high17%1

1-year return-76%1

3-year return-61%1

5-year return-68%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-61% over three years and -68% over five), behind 90% of the market.

It's down 76% over the past year, now 83% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-27%), over three months (-76%) and so far this year (-82%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on EyePoint, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

EYPTEyePoint

Revenue FY25$31M

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-9%1

Revenue, next 1Y-95%1

Revenue, next 3Y, CAGR+34%10

Revenue, next 5Y, CAGR+66%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 34%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 34%/yr from here.

The runway holds up: revenue is set to grow 66%/yr over five years.10/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

WEAKNESSES

Revenue fell 9%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK1 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-27%1

3-month return-76%1

YTD return-82%1

MID & LONG-TERM▾SCORE

% of 52-week high17%1

1-year return-76%1

3-year return-61%1

5-year return-68%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-61% over three years and -68% over five), behind 90% of the market.

It's down 76% over the past year, now 83% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-27%), over three months (-76%) and so far this year (-82%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on EyePoint, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community